Lv53
1580 积分 2024-01-18 加入
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
18天前
已完结
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
1个月前
已完结
Non-small-cell lung cancer
1个月前
已完结
Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma
1个月前
已完结
Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
2个月前
已完结
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
2个月前
已完结
Therapeutic options in hepatocellular carcinoma: a comprehensive review
2个月前
已完结
Artificial intelligence in liver cancer — new tools for research and patient management
2个月前
已完结
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
2个月前
已完结
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
2个月前
已完结
皖公网安备34019202002308
